GlassScriptPhysician profile
Nelly Awkar Lazo
NPI 1326351537
$18,779.14
in general payments reported to CMS, 2019-2025
89 companies · $2,903 in 2025
The $2,903 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $2,288 · 2021: $2,154 · 2022: $3,132 · 2023: $3,346 · 2024: $3,244 · 2025: $2,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,484 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,484.22 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,442.50 | 2019-2025 | |
| Incyte Corporation | $989.99 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $900.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $782.77 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $760.01 | 2019-2025 | Calquence, Lynparza, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $702.17 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Celgene Corporation | $626.01 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Glaxosmithkline, LLC. | $617.95 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Amgen INC. | $554.14 | 2019-2023 | Blincyto, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $536.83 | 2019-2025 | Alunbrig, Fruzaqla, Iclusig |
| Genentech USA, INC. | $524.09 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Janssen Biotech, INC. | $490.82 | 2019-2025 | Imbruvica, Erleada, Darzalex |
| Exelixis INC. | $477.24 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $455.63 | 2019-2023 | Imbruvica |
| Seagen INC. | $438.95 | 2019-2023 | Tukysa, Adcetris, Padcev |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $425.46 | 2019-2025 | |
| Abbvie INC. | $368.79 | 2019-2025 | Venclexta |
| Eisai INC. | $360.14 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $324.37 | 2019-2025 | |
| Array Biopharma INC | $316.33 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Karyopharm Therapeutics INC. | $306.56 | 2021-2025 | Xpovio |
| Puma Biotechnology, INC. | $297.65 | 2019-2024 | Nerlynx |
| Gilead Sciences, INC. | $287.11 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $278.51 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $271.38 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Daiichi Sankyo INC. | $265.51 | 2020-2025 | Enhertu, Vanflyta |
| Taiho Oncology, INC. | $265.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.44 | 2019-2024 | Libtayo |
| Foundation Medicine, INC. | $207.75 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $202.59 | 2023-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $177.04 | 2021-2024 | Ultomiris |
| Emd Serono, INC. | $169.17 | 2019-2025 | Bavencio |
| Sobi, INC | $166.89 | 2022-2025 | |
| Pharmaessentia USA Corporation | $156.26 | 2022-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.09 | 2019-2025 | Gilotrif |
| Blueprint Medicines Corporation | $134.85 | 2020-2024 | Ayvakit |
| Stemline Therapeutics INC. | $126.56 | 2022-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $123.50 | 2022-2024 | Somatuline Depot, Onivyde |
| Janssen Pharmaceuticals, INC | $121.75 | 2019-2023 | Xarelto |
| Octapharma USA, INC. | $119.94 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $117.63 | 2020-2025 | Pyrukynd |
| Kite Pharma, INC. | $114.07 | 2021-2023 | Yescarta |
| Cti Biopharma Corp. | $110.96 | 2022-2023 | Vonjo |
| Eusa Pharma (US) LLC | $109.49 | 2019-2021 | |
| Adc Therapeutics America, INC. | $105.96 | 2022-2025 | |
| Myovant Sciences INC. | $105.29 | 2021-2022 | |
| Beigene USA, INC. | $100.57 | 2021-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $98.41 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Aveo Pharmaceuticals, INC. | $89.84 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $86.81 | 2020-2024 | Provenge |
| Morphosys, US INC. | $85.39 | 2021-2023 | Monjuvi |
| Epizyme, INC. | $77.38 | 2020-2022 | |
| Mirati Therapeutics, INC. | $73.48 | 2023-2024 | Krazati |
| Verastem, INC. | $71.70 | 2019-2020 | |
| Ge Healthcare | $66.36 | 2021-2025 | |
| Emmaus Medical, INC. | $62.41 | 2019-2020 | |
| Macrogenics, INC. | $56.48 | 2022 | |
| Sirtex Medical INC | $56.10 | 2020-2024 | Sir-Spheres Microspheres |
| Dova Pharmaceuticals | $55.43 | 2020-2021 | |
| Immunogen, INC. | $54.04 | 2023 | Elahere |
| Beone Medicines USA, INC. | $51.20 | 2025 | Brukinsa |
| Novocure INC. | $49.97 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $47.80 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $46.23 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $44.46 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $43.82 | 2024-2025 | Monoferric, Cosela |
| Apellis Pharmaceuticals, INC. | $40.94 | 2022-2023 | Empaveli |
| Deciphera Pharmaceuticals INC. | $40.92 | 2023-2024 | Qinlock, Tgct |
| Immunocore Limited | $37.90 | 2024 | Kimmtrak |
| Csl Behring | $31.70 | 2020 | |
| Tesaro, INC. | $30.63 | 2019 | |
| Caris Mpi, INC. | $30.22 | 2025 | Mi Cancer Seek |
| Chiesi USA, INC. | $29.93 | 2020-2023 | Ferriprox |
| Adaptive Biotechnologies Corporation | $29.67 | 2021 | |
| Janssen Scientific Affairs, LLC | $29.29 | 2019 | |
| Boston Scientific Corporation | $28.05 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Spectrum Pharmaceuticals INC. | $27.67 | 2019 | |
| Azurity Pharmaceuticals, INC. | $26.26 | 2025 | Danziten |
| Geron Corporation | $25.44 | 2025 | Rytelo |
| Secura Bio, INC. | $25.32 | 2019 | |
| Syndax Pharmaceuticals, INC. | $24.77 | 2025 | |
| Clovis Oncology, INC. | $23.38 | 2020 | |
| Servier Pharmaceuticals LLC | $22.92 | 2025 | |
| Tg Therapeutics, INC. | $22.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.57 | 2019 | |
| Acceleron Pharma, INC. | $21.17 | 2021 | |
| Apo-Pharma USA, INC. | $19.68 | 2019 | |
| West Therapeutics Development, LLC | $15.09 | 2019 | |
| Recordati_rare_diseases_inc. | $14.16 | 2025 | Enjaymo |
Drugs and devices associated with these payments
Keytruda $467Imbruvica $390Cabometyx $320Orgovyx $314Opdivo $286Lynparza $279Jakafi $274Kisqali $230Xtandi $189Adcetris $184Xpovio $182Reblozyl $180Monjuvi $177Braftovi $170Mektovi $170Pluvicto $165Lenvima $162Tukysa $160Opdualag $155Lorbrena $150Fabhalta $145Jemperli $142Verzenio $140Scemblix $139Elrexfio $138Calquence $136Alunbrig $134Piqray $130Libtayo $124Enhertu $121Sarclisa $120Inqovi $117Lonsurf $117Ibrance $116Elahere $115Jaypirca $115Trodelvy $112Talzenna $107Ultomiris $103Nubeqa $99.89Promacta $98.53Welireg $98.50Orserdu $95.86Besremi $95.46Vonjo $93.27Tivdak $93.02Venclexta $91.97Xalkori $91.06Pemazyre $90.54Fotivda $89.84Brukinsa $88.57Erleada $88.55Doptelet $85.07Tecentriq $83.67Zejula $83.28Onivyde $82.32Somatuline Depot $82.32Polivy $75.64Pomalyst $75.26Fruzaqla $74.53Krazati $73.48Darzalex $72.60Pyrukynd $71.07Tagrisso $69.66Padcev $68.13Lutathera $67.05Ojjaara $63.49Stivarga $61.87Vitrakvi $61.87Provenge $59.90Bosulif $58.08Phesgo $55.65Itovebi $55.16Imfinzi $52.22Vyloy $49.69Iclusig $48.19Amtagvi $47.80Epkinly $47.04Zepzelca $46.23Tavalisse $45.98Rezlidhia $45.98Mekinist $43.73Xospata $41.39Qinlock $40.92Rybrevant $40.82Zynyz $39.26Kimmtrak $37.90Retevmo $35.05Kyprolis $33.63Blincyto $33.63Ninlaro $31.62Akeega $31.14Mi Cancer Seek $30.22Gilotrif $29.63Oxbryta $29.19Empaveli $28.47Therasphere Y90 Glass Microspheres 10 Gbq $28.05Zynlonta $27.98Keytruda Qlex $27.94Danziten $26.26
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelly Awkar Lazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.